Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen
September 21, 2018 06:30 ET
|
Sarepta Therapeutics, Inc.
-- Relying upon Scientific Advisory Group input, Sarepta will seek further scientific advice from European Medicines Agency on a possible path to bring eteplirsen to patients in Europe -- ...
Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
September 07, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global biopharmaceutical company focused on the discovery and development of precision genetic...
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
September 04, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2018 18:36 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
August 20, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
August 08, 2018 16:02 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools
August 08, 2018 16:01 ET
|
Sarepta Therapeutics, Inc.
-- Sarepta expands its presence in gene therapy and broadens its reach with license to up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s gene therapy...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2018 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events
July 25, 2018 16:34 ET
|
Sarepta Therapeutics, Inc.
-- Out-of-specification lot resulted from the presence of trace levels of DNA fragment in research-grade raw material plasmid sourced from third-party manufacturer -- -- Fragment fully...
Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018
July 20, 2018 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision...